What is Leerink Partnrs’ Estimate for MREO Q1 Earnings?

Mereo BioPharma Group plc (NASDAQ:MREO) – Research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Mereo BioPharma Group in a research report issued to clients and investors on Wednesday, March 26th. Leerink Partnrs analyst J. Schwartz expects that the company will earn $0.07 per share for the quarter. The consensus estimate for Mereo BioPharma Group’s current full-year earnings is ($0.03) per share. Leerink Partnrs also issued estimates for Mereo BioPharma Group’s Q2 2025 earnings at $0.05 EPS, Q3 2025 earnings at ($0.02) EPS, Q4 2025 earnings at ($0.02) EPS, FY2025 earnings at $0.08 EPS and FY2026 earnings at ($0.03) EPS.

Other equities analysts also recently issued research reports about the company. Lifesci Capital assumed coverage on Mereo BioPharma Group in a research note on Tuesday, December 24th. They set an “outperform” rating and a $10.00 price target for the company. Needham & Company LLC restated a “buy” rating and set a $7.00 price target on shares of Mereo BioPharma Group in a report on Wednesday, March 26th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $7.00 price objective on shares of Mereo BioPharma Group in a research note on Tuesday, March 18th. JPMorgan Chase & Co. initiated coverage on Mereo BioPharma Group in a research report on Thursday, March 27th. They set an “overweight” rating and a $7.00 price target for the company. Finally, Jefferies Financial Group initiated coverage on Mereo BioPharma Group in a research report on Friday, December 6th. They set a “buy” rating and a $7.00 target price for the company. Six investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Mereo BioPharma Group presently has a consensus rating of “Buy” and a consensus price target of $7.71.

Mereo BioPharma Group Price Performance

NASDAQ:MREO opened at $2.25 on Monday. Mereo BioPharma Group has a one year low of $2.16 and a one year high of $5.02. The company has a market cap of $349.08 million, a PE ratio of -37.50 and a beta of 1.03. The firm has a 50-day moving average of $2.71 and a 200-day moving average of $3.46.

Mereo BioPharma Group (NASDAQ:MREO) last announced its quarterly earnings results on Wednesday, March 26th. The company reported ($0.01) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.03).

Institutional Trading of Mereo BioPharma Group

Hedge funds and other institutional investors have recently bought and sold shares of the company. Janus Henderson Group PLC increased its holdings in shares of Mereo BioPharma Group by 38.7% in the fourth quarter. Janus Henderson Group PLC now owns 17,122,563 shares of the company’s stock worth $59,843,000 after purchasing an additional 4,776,697 shares during the period. Rock Springs Capital Management LP raised its position in shares of Mereo BioPharma Group by 0.7% during the 4th quarter. Rock Springs Capital Management LP now owns 9,599,170 shares of the company’s stock valued at $33,597,000 after buying an additional 65,000 shares in the last quarter. Frazier Life Sciences Management L.P. lifted its holdings in shares of Mereo BioPharma Group by 15.8% during the 3rd quarter. Frazier Life Sciences Management L.P. now owns 5,097,779 shares of the company’s stock worth $20,952,000 after acquiring an additional 696,408 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in Mereo BioPharma Group in the fourth quarter worth $3,377,000. Finally, Tema Etfs LLC bought a new position in Mereo BioPharma Group in the fourth quarter valued at $3,117,000. Institutional investors own 62.83% of the company’s stock.

About Mereo BioPharma Group

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.